QUARTERLY PROFITS

  • novo nordisk raises outlook fuelled by obesity drug demand

    Novo Nordisk raises outlook fuelled by obesity drug demand

    ​​​​​​Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected quarterly profits as the Danish drugmaker races to boost output of its hugely popular weight-loss drug Wegovy and fend off competition from rival Eli Lilly.

Join the community of 2M+ industry professionals

Subscribe to our Daily Newsletter

By continuing you agree to our Privacy Policy & Terms & Conditions

Download ETHealthworld App for Realtime updates

Seamless reading experience. Save your favourite.

Scan to download App

Download ETHealthworld App for Realtime updates of content you follow

  • Seamless reading experience
  • Save your favourite articles
Advertisement
Advertisement